Immunomet Therapeutics, Inc.

Immunomet Therapeutics, Inc. company information, Employees & Contact Information

ImmunoMet Therapeutics is a clinical stage biotech targeting cellular metabolism to develop novel anti-fibrotic and anti-tumor therapies. Our lead molecule, IM156, is a protein complex 1 (PC1) inhibitor that targets the Oxidative Phosphorylation (OXPHOS) pathway in mitochondria and decreases aberrant cell growth in fibrosis and select cancer cells. IM156 is the first potent PC1 inhibitor to complete Phase 1 with a good tolerability. In fibrosis, ImmunoMet is currently conducting a Phase 1 study in healthy volunteers and plan to progress into Phase 2 PoC study in IPF patients in 4Q2021. The company was founded in 2015, is a spin-off from HanAll Biopharma, a Korean midsized public company, and has raised $31 MM post-spin-off.

Company Details

Employees
8
Founded
-
Address
Houston, Texas
Phone
119196161923
Email
in****@****met.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Houston, Texas
Looking for a particular Immunomet Therapeutics, Inc. employee's phone or email?

Immunomet Therapeutics, Inc. Questions

Top Immunomet Therapeutics, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant